ONCODES.PREC.MED. EO-34
Research ONCODES.PREC.MED. EO-34 (ZR8) on Bullrun: market cap EUR 6.40M, P/E 1.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZR8
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 6.40M
- P/E1.1
- Financial periodFY2024
- RevenueEUR 207.04K
- Revenue growth-80.7%
- Net income-EUR 7.21M
- Gross margin-3039.8%
Valuation Snapshot
latest market cap is EUR 6.40M; P/E is 1.1.
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease.
Frequently asked questions
What is ONCODES.PREC.MED. EO-34's market cap?
ONCODES.PREC.MED. EO-34's market capitalization is EUR 6.40M.
What is ONCODES.PREC.MED. EO-34's P/E ratio?
ONCODES.PREC.MED. EO-34's price-to-earnings (P/E) ratio is 1.1.
What does ONCODES.PREC.MED. EO-34 do?
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer;